Home / Business and Economy / Big Money Buys Neurocrine: Stock Surges 27%
Big Money Buys Neurocrine: Stock Surges 27%
12 Jul
Summary
- Neurocrine's Q1 sales exceeded $800 million.
- INGREZZA sales grew 44% year-over-year.
- Institutional investors are heavily buying NBIX shares.
Neurocrine Biosciences (NBIX) demonstrated a strong financial performance in its first quarter of fiscal 2026. The biopharmaceutical company announced net product sales exceeding $800 million. This significant revenue was largely propelled by its drug INGREZZA, which achieved an impressive 44% year-over-year growth.
Net income for the quarter was approximately $200 million. Neurocrine also highlighted its promising product pipeline, currently comprising 12 active programs with an additional five slated for launch within the current year. This robust pipeline, coupled with strong financial results, has attracted substantial attention from institutional investors.
The company's stock has seen a notable increase, rising 27% year-to-date. This upward trend is supported by significant "Big Money" investor demand, indicating strong institutional backing and confidence in Neurocrine's future prospects and fundamental strength.
